6 SUVs That Will Have Massive Price Drops in the Summer of 2025
Discover More:
Try This:
Recently, we've seen Ford offer aggressive discounting as the manufacturer prioritizes U.S. production and tries to clear dealer lots, per USA Today report. Electric vehicles and luxury SUVs are especially vulnerable, as demand softens and competition heats up in both the compact and high-end markets.
According to Fix, buyers should expect discounts ranging from $3,000 to $15,000 off MSRP, especially if they shop in June or July and compare dealership offers. This summer's market conditions offer a rare chance to score a premium SUV at a much lower price.
The Porsche Macan EV, which debuted with high expectations, is now facing sluggish demand and growing inventory at dealerships.
According to Edmunds, the 2025 Macan Electric starts at $75,300, but dealers are already offering discounts of $10,000 to $15,000 to move unsold models. Motorauthority also reports that the new rear-wheel-drive base Macan EV is cheaper than last year's entry-level model, reflecting the pressure on Porsche to stay competitive.
Buyers interested in a luxury electric SUV will find this summer an excellent time to negotiate a deal, especially as more affordable and updated EVs hit the market.
Trending Now:
The Alfa Romeo Stelvio, once a standout in the luxury SUV segment, is now among the fastest-depreciating vehicles in its class.
'The Stelvio's steep 67% depreciation makes it a bargain, with cuts up to $12,000 as dealers clear out inventory,' according to CarEdge. The site notes the Stelvio loses about 67% of its value within five years, with a five-year resale value of just $18,957.
Shoppers looking for a European luxury SUV can expect some of the steepest price cuts on the Stelvio this summer, making it a bargain for those willing to accept higher long-term depreciation.
The Chevrolet Blazer EV, another electric SUV facing stiff competition and slow sales, is likely to be heavily discounted in the coming months.
'Dealers are motivated to offer $5,000 to $10,000 off MSRP to move unsold Blazer EVs,' Fix said.
As automakers deal with high inventory and tariff pressures, buyers should monitor dealership promotions and be ready to negotiate. This summer presents a unique chance to get a high-tech electric SUV at a substantial discount.
Ford's Mustang Mach-E, a key player in the electric SUV market, is experiencing excess inventory and slow sales in 2025.
'Ford's Mustang Mach-E faces excess inventory, driving discounts of $5,000 to $10,000, especially on 2024 models,' Fix shared.
Ford Authority reports that Ford has launched an employee pricing program for everyone, offering nationwide discounts on both 2024 and 2025 Mach-E models. These incentives, which can total $5,000 to $10,000 off MSRP, are available through July and include additional perks like complimentary home chargers.
The Volvo XC90, a mainstay in the luxury SUV market, is expected to see significant price drops as dealers clear out older models ahead of a refresh.
Car and Driver reports that the 2025 XC90 starts at $58,695, but local dealers are discounting current inventory by $7,000 to $12,000 to make room for the updated version.
Buyers can expect additional incentives and low financing rates, especially on the outgoing model, making this summer a great time to buy a luxury SUV with a reputation for safety and reliability.
The Ford Escape, a popular compact SUV, is also seeing major price reductions as the 2025 model year approaches.
According to CarBuzz, the 2025 Escape is cheaper than the 2024 version, with price cuts starting at $1,395 on the base trim and up to $2,100 for the plug-in hybrid. Dealers are offering additional discounts of $3,000 to $6,000 to clear out remaining 2024 inventory, especially as demand for compact SUVs slows.
Buyers interested in an affordable, fuel-efficient SUV will find the Escape especially attractive this summer, with deep discounts and incentives available.
Editor's note: Photos are for representational purposes.
More From GOBankingRates
Mark Cuban Warns of 'Red Rural Recession' -- 4 States That Could Get Hit Hard
Warren Buffett: 10 Things Poor People Waste Money On
10 Cars That Outlast the Average Vehicle
This article originally appeared on GOBankingRates.com: 6 SUVs That Will Have Massive Price Drops in the Summer of 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical technology company Hologic (NASDAQ:HOLX) will be reporting earnings this Wednesday afternoon. Here's what investors should know. Hologic met analysts' revenue expectations last quarter, reporting revenues of $1.01 billion, down 1.2% year on year. It was a slower quarter for the company, with a slight miss of analysts' full-year EPS guidance estimates and full-year revenue guidance meeting analysts' expectations. Is Hologic a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hologic's revenue to be flat year on year at $1.01 billion, slowing from the 2.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.9% on average. Looking at Hologic's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Hologic is up 2.8% during the same time and is heading into earnings with an average analyst price target of $69.93 (compared to the current share price of $66.99). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
CONMED (CNMD) Q2 Earnings: What To Expect
Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here's what to look for. CONMED beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $321.3 million, up 2.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is CONMED a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting CONMED's revenue to grow 1.9% year on year to $338.3 million, slowing from the 4.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street's revenue estimates three times over the last two years. Looking at CONMED's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. CONMED is down 4% during the same time and is heading into earnings with an average analyst price target of $66.60 (compared to the current share price of $50.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings
Packaged foods company Kraft Heinz (NASDAQ:KHC) will be reporting results this Wednesday before market open. Here's what investors should know. Kraft Heinz met analysts' revenue expectations last quarter, reporting revenues of $6.00 billion, down 6.4% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' EBITDA estimates but full-year EPS guidance missing analysts' expectations. Is Kraft Heinz a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Kraft Heinz's revenue to decline 3.1% year on year to $6.27 billion, in line with the 3.6% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.64 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 4 downward revisions over the last 30 days (we track 10 analysts). Looking at Kraft Heinz's peers in the shelf-stable food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Lamb Weston delivered year-on-year revenue growth of 4%, beating analysts' expectations by 5.7%, and McCormick reported flat revenue, in line with consensus estimates. Lamb Weston traded up 19.3% following the results while McCormick was also up 3.6%. Read our full analysis of Lamb Weston's results here and McCormick's results here. There has been positive sentiment among investors in the shelf-stable food segment, with share prices up 3.8% on average over the last month. Kraft Heinz is up 9.3% during the same time and is heading into earnings with an average analyst price target of $30.18 (compared to the current share price of $28.22). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
